After a complete response letter and a subsequent biologics license application resubmission, denileukin diftitox has been approved by the FDA.
Approval Alert | Denileukin Diftitox in Relapsed/Refractory Cutaneous T-Cell Lymphoma
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
3
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
4
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
5